Clinical Pearls
Alzheimer’s disease affects clinicians as well
Caregivers often experience burnout and compassion fatigue.
Your search for Alzheimer disease returned 271 results
Slideshow
Alzheimer disease
The most common dementia in the elderly, Alzheimer disease places tremendous physical and emotional strain on patient and caregiver alike.
Cardiovascular Disease Information Center
Statins may reduce risk of Alzheimer’s disease
Depending on race, sex, and ethnicity, the right statin type may lower the risk of Alzheimer disease.
Web Exclusives
Running may lower Alzheimer-related mortality risk
Patients who ran more than 15.3 miles per week had a 40% reduced risk of dying from Alzheimer disease.
Neurology Information Center
Prevalence of Alzheimer’s, Related Dementia Set to Double
Alzheimer's disease and related dementias burden is expected to increase to 3.3% in 2060.
Advisor Forum
Diabetes, high LDL speed Alzheimer’s decline
A history of diabetes or high cholesterol (especially LDL) can speed cognitive decline in patients with Alzheimer's disease.
Neurology Information Center
Sleep disorders may increase risk for Alzheimer’s disease
Obstructive sleep apnea and sleep-disordered breathing are associated with amyloid deposition.
Neurology Information Center
Age, Sex, APOE Genotype Identify Alzheimer’s, Dementia Risk
Three factors help identify absolute 10-year risk of Alzheimer's disease, all dementia for different groups.
Evidence-Based Medicine
Antipsychotic meds associated with reduced survival in patients with Alzheimer’s disease
Level 2: Mid-level evidenceIn April 2008, the Dementia Antipsychotic Withdrawal Trial (DART-AD) showed that stopping antipsychotic treatment did not worsen cognitive, functional, or behavioral status in most elderly patients with Alzheimer’s disease (PLoS Med. 2008;5:e76; accessed April 8, 2009). Based on results of short-term trials that indicated an increased mortality risk, the FDA has previously…
Neurology Information Center
Trials for Investigational Alzheimer’s Treatment Lanabecestat Discontinued
The independent data monitoring committee (IDMC) concluded that the 2 trials (AMARANTH and DAYBREAK-ALZ) investigating the treatment in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints of change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale.
- Loading...
Loading...
Next post in Neurology Information Center
Loading... 
Loading...